MRK scores an A+ grade for Profitability, aided by high gross and EBITDA margins of 78% and 46%, respectively. Moreover, it ...

Impax Asset Management, an investment management company, released its “Impax US Sustainable Economy Fund” second-quarter ...

The highest-paying dividend stocks in the Dow Jones Industrial Average right now are Verizon Communications (NYSE: VZ), ...

German science and technology firm Merck is showcasing its latest materials innovations at K-Display 2025 in Seoul, ...

JCD Group has, in recent years, completed 440,000 sq. ft of new buildings in Blarney Business Park with occupiers including ...

The number of biopharma professionals let go has increased year over year for three straight months. In July, nearly 8,000 ...

LASCO Distributors reported a 15.3 per cent drop in net profit to $304 million for Q1 2025/26, with revenues dipping slightly ...

Women with an advanced form of womb cancer have been given fresh hope after a new treatment was given the green light for ...

Halozyme Therapeutics reports a record Q2 2025, with 41% revenue growth. Discover raised guidance, strong catalysts, and shareholder-focused initiatives.

From tariffs to drug pricing to the FDA, biopharma CEOs find themselves pulled into policy discussions on this year’s second quarter earnings calls.

Donald Trump plans to impose new tariffs on pharmaceuticals and semiconductors to boost manufacturing in the US.

CoreWeave purchased a research & development building at the NEST campus in Kenilworth, N.J., plus an adjacent 27 acres for ...